Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholinergic System Clear all
Completed No phase listed Observational Accepts healthy volunteers

Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease

NCT00058721
View directory record Official record
Conditions
Parkinson Disease
Interventions
I-123-5-IA85380
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated No phase listed Observational

Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease

NCT05034263
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 3 Interventional

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

NCT00000172
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Galantamine
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193
View directory record Official record
Conditions
Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
27
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Anti-inflammatory Actions of Osteopathic Manipulative Treatment

NCT04177264
View directory record Official record
Conditions
Inflammation
Interventions
Occipito-Atlantal Decompression (OA DC), Sham Occipito-Atlantal Decompression (Sham OA DC), Splenic Lymphatic Pump Technique (SpLPT), Sham Splenic Lymphatic Pump Technique (Sham SpLPT), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)
Procedure · Device
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

NCT03674541
View directory record Official record
Conditions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Exercise Intolerance, Dysautonomia, Low Ventricular Filling Pressures (Preload Failure), Postural Orthostatic Tachycardia Syndrome, Orthostatic Hypotension, Fibromyalgia
Interventions
Pyridostigmine Bromide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT05024058
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Ligelizumab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

Stimulation of Cingulo-opercular Alertness Network

NCT04817891
View directory record Official record
Conditions
Lewy Body Disease, Lewy Body Variant of Alzheimer Disease, Lewy Body Dementia With Behavioral Disturbance
Interventions
HD-tDCS
Device
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

NCT06887192
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA, Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated No phase listed Observational

Clinical Autonomic Disorders: A Training Protocol

NCT02154009
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Pseudopheochromocytoma, Healthy Volunteers, Neurocardiogenic Syncope, Postural Tachycardia Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651
View directory record Official record
Conditions
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
North Miami Beach, Florida • Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Inflammation and Cognition

NCT03384784
View directory record Official record
Conditions
HIV Associated Cognitive Motor Complex
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Study of Donepezil in Fragile X Syndrome

NCT01120626
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
donepezil, sugar pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional

Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV

NCT03904186
View directory record Official record
Conditions
Human Immunodeficiency Virus, Smoking Cessation, Smoking, Cigarette, Smoking, Anxiety, Depression, Nicotine Dependence
Interventions
QUIT, Time-Matched Control (TM)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Pharmacological Modulation of Brain Oscillations in Memory Processing

NCT05594017
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorders, Memory Loss
Interventions
Scopolamine (0.4mg), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

NCT00006399
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, Estrogen, Progesterone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
45 Years to 85 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Jul 22, 2026, 5:53 AM EDT
Completed No phase listed Observational

Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome

NCT00565526
View directory record Official record
Conditions
Sjogren's Syndrome, Dysautonomia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

NCT07459660
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 91 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Doral, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain

NCT02822989
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Musculoskeletal Pain
Interventions
Vagus nerve stimulation, Sham vagus nerve stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis

NCT06555562
View directory record Official record
Conditions
Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Ultrasound Stimulation, Non-active ultrasound stimulation
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
22 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)

NCT05459753
View directory record Official record
Conditions
Parkinson Disease, Progressive Supranuclear Palsy
Interventions
(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET, Dihydrotetrabenazine (DTBZ) PET
Radiation
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease

NCT00737217
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Behavioral assessment/questionnaire
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jul 22, 2026, 5:53 AM EDT
Completed No phase listed Observational

Cholinergic Receptor Imaging in Dystonia

NCT02689466
View directory record Official record
Conditions
Cervical Dystonia, Dystonia, Movement Disorder, Focal Dystonia
Interventions
[18F]FP-TZTP
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 3 Interventional

Memory Impairment Study (Mild Cognitive Impairment Study)

NCT00000173
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, Vitamin E
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jul 22, 2026, 5:53 AM EDT